Roche Holdings Ltd. (RHHBY) recently announced that the US Food and Drug Administration (FDA) has approved its skin cancer drug Erivedge (vismodegib) for the treatment of patients with advanced basal cell carcinoma (BCC). The once-daily oral drug is approved for use in patients whose cancer has relapsed after surgery or whose cancer has spread to other parts of the body or who cannot be treated with surgery or radiation.
We note that Roche had submitted the new drug application (NDA) for … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards